JP2015526497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015526497A5 JP2015526497A5 JP2015529082A JP2015529082A JP2015526497A5 JP 2015526497 A5 JP2015526497 A5 JP 2015526497A5 JP 2015529082 A JP2015529082 A JP 2015529082A JP 2015529082 A JP2015529082 A JP 2015529082A JP 2015526497 A5 JP2015526497 A5 JP 2015526497A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- selective agonist
- brl37344
- pharmaceutically acceptable
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 10
- 239000000556 agonist Substances 0.000 claims 7
- PBAPPPCECJKMCM-IBGZPJMESA-N mirabegron Chemical compound S1C(N)=NC(CC(=O)NC=2C=CC(CCNC[C@H](O)C=3C=CC=CC=3)=CC=2)=C1 PBAPPPCECJKMCM-IBGZPJMESA-N 0.000 claims 4
- 229960001551 mirabegron Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- ZGGNJJJYUVRADP-ACJLOTCBSA-N 2-[4-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid Chemical group C([C@@H](C)NC[C@H](O)C=1C=C(Cl)C=CC=1)C1=CC=C(OCC(O)=O)C=C1 ZGGNJJJYUVRADP-ACJLOTCBSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- RDJQCOBTKKAQAH-FPOVZHCZSA-N Amibegron Chemical compound C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 RDJQCOBTKKAQAH-FPOVZHCZSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229950008231 amibegron Drugs 0.000 claims 2
- FUZBPOHHSBDTJQ-CFOQQKEYSA-L disodium;5-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate Chemical compound [Na+].[Na+].C1([C@@H](O)CN[C@@H](CC=2C=C3OC(OC3=CC=2)(C([O-])=O)C([O-])=O)C)=CC=CC(Cl)=C1 FUZBPOHHSBDTJQ-CFOQQKEYSA-L 0.000 claims 2
- NQIZCDQCNYCVAS-RQBPZYBGSA-N ethyl 2-[[(7s)-7-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]acetate;hydron;chloride Chemical compound Cl.C1([C@@H](O)CN[C@H]2CCC3=CC=C(C=C3C2)OCC(=O)OCC)=CC=CC(Cl)=C1 NQIZCDQCNYCVAS-RQBPZYBGSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical group NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 claims 2
- -1 CR58611 Chemical compound 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229950006768 phenylethanolamine Drugs 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 0 *NCC(C1=CCCC=C1)O Chemical compound *NCC(C1=CCCC=C1)O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP201231343 | 2012-08-29 | ||
| ES201231343A ES2394349B1 (es) | 2012-08-29 | 2012-08-29 | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| PCT/ES2013/070611 WO2014033343A1 (es) | 2012-08-29 | 2013-08-28 | Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526497A JP2015526497A (ja) | 2015-09-10 |
| JP2015526497A5 true JP2015526497A5 (enExample) | 2016-10-13 |
| JP6539206B2 JP6539206B2 (ja) | 2019-07-03 |
Family
ID=47520452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015529082A Active JP6539206B2 (ja) | 2012-08-29 | 2013-08-28 | 肺高血圧症の治療のためのベータ−３アドレナリン受容体アゴニストの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10532038B2 (enExample) |
| EP (1) | EP2891490B1 (enExample) |
| JP (1) | JP6539206B2 (enExample) |
| DK (1) | DK2891490T3 (enExample) |
| ES (2) | ES2394349B1 (enExample) |
| WO (1) | WO2014033343A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070689A2 (en) | 2015-10-23 | 2017-04-27 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
| WO2022198259A1 (en) * | 2021-03-25 | 2022-09-29 | The Heart Research Institute Ltd | Treatment methods for pulmonary arterial hypertension |
| CA3212587A1 (en) * | 2021-03-31 | 2022-10-06 | Jr. Raymond E. Stevens | Compositions of micronized solabegron and methods of use |
| IT202300021417A1 (it) | 2023-10-13 | 2025-04-13 | Univ Pisa | Agonisti o attivatori del recettore adrenergico beta-3 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0006735B1 (en) | 1978-06-28 | 1983-06-15 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| DE3061334D1 (en) | 1979-06-16 | 1983-01-20 | Beecham Group Plc | Ethanamine derivatives, their preparation and use in pharmaceutical compositions |
| EP0021636B1 (en) | 1979-06-16 | 1982-12-01 | Beecham Group Plc | Secondary amines, their preparation and use in pharmaceutical compositions |
| ES8800842A1 (es) | 1985-03-01 | 1987-12-01 | Beecham Group Plc | Un procedimiento para preparar una formulacion veterinariamente aceptable de ariletanolaminas promotora del crecimiento. |
| GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| IT1204416B (it) | 1986-06-27 | 1989-03-01 | Midy Spa | Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini |
| GB8801306D0 (en) | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
| ATE144139T1 (de) | 1989-06-13 | 1996-11-15 | Sanofi Sa | Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden |
| GB8925032D0 (en) | 1989-11-06 | 1989-12-28 | Ici Plc | Chemical compounds |
| US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| ATE185564T1 (de) | 1992-08-31 | 1999-10-15 | Sankyo Co | Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung |
| US5578638A (en) | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| CA2145257A1 (en) | 1994-03-23 | 1995-09-24 | Takashi Fujita | Thiazolidine and oxazolidine derivatives, their preparation and their medical use |
| US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| PT801059E (pt) | 1994-11-29 | 2001-10-30 | Dainippon Pharmaceutical Co | Derivado indol |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| ES2158996T3 (es) | 1995-09-21 | 2001-09-16 | Lilly Co Eli | Agonistas beta3 adrenergicos selectivos. |
| AU715216B2 (en) | 1995-10-26 | 2000-01-20 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
| CA2242351C (en) | 1996-01-10 | 2003-03-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel tricyclic compounds and drug compositions containing the same |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| AU712057B2 (en) | 1996-06-07 | 1999-10-28 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity |
| ES2171839T3 (es) | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| BR9807096A (pt) | 1997-01-28 | 2000-04-18 | Merck & Co Inc | Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica |
| ES2149742T1 (es) | 1997-07-03 | 2000-11-16 | Asahi Chemical Ind | Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos. |
| WO2002006276A1 (en) | 2000-07-13 | 2002-01-24 | Eli Lilly And Company | Beta3 adrenergic agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US20040242485A1 (en) | 2003-05-30 | 2004-12-02 | Takashi Kadowaki | Compositions and methods for the amelioration of leptin resistance |
| EP3459558B1 (en) * | 2010-06-25 | 2020-07-29 | Aston University | Glycoproteins having lipid mobilizing properties and therapeutic uses thereof |
| CN102764438A (zh) | 2012-01-30 | 2012-11-07 | 林曙光 | β3肾上腺素受体激动剂的新用途 |
-
2012
- 2012-08-29 ES ES201231343A patent/ES2394349B1/es not_active Withdrawn - After Issue
-
2013
- 2013-08-28 DK DK13785891.6T patent/DK2891490T3/da active
- 2013-08-28 US US14/424,861 patent/US10532038B2/en active Active
- 2013-08-28 ES ES13785891T patent/ES2863749T3/es active Active
- 2013-08-28 WO PCT/ES2013/070611 patent/WO2014033343A1/es not_active Ceased
- 2013-08-28 EP EP13785891.6A patent/EP2891490B1/en active Active
- 2013-08-28 JP JP2015529082A patent/JP6539206B2/ja active Active